VX-680/MK-0457 - Aurora kinase inhibitor oncolytic

被引：8

作者：

Wang, Y. ^{[1
]}

Serradell, N. ^{[1
]}

机构：

[1] Prous Sci, E-08080 Barcelona, Spain

来源：

DRUGS OF THE FUTURE | 2007年 / 32卷 / 02期

关键词：

D O I：

10.1358/dof.2007.032.02.1076496

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

VX-680/MK-0457 is a small-molecule Aurora kinase inhibitor with inhibition constants (K(i)) of 0.6, 18 and 4.6 nM for Aurora kinase A, B and C, respectively; it also inhibits Flt-3 and AN kinases, particularly mutant forms. The compound displays potent antitumor activity in a broad range of cancer cell lines and is well tolerated in preclinical studies. A phase I clinical trial of VX-680/MK-0457 was carried out in patients with chronic myeloid leukemia (CML) or acute lymphocytic leukemia (ALL) with the T315l Bcr-Abl resistance mutation and patients with refractory JAK2-positive myeloproliferative disease. VX-680/MK-0457 demonstrated encouraging antitumor activity and a good overall safety profile.

引用

页码：144 / 147

页数：4

共 22 条

[1] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

[2]

Charrier J. D., 2004, U.S. Patent, Patent No. [2,004,049,032, 2004049032]

[3]

Charrier J.-D., 2004, Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase, Patent No. [2004000833, WO 2004000833]

[4]

CHARRIER JD, Patent No. 1746093

[5]

CHARRIER JD, 2005, Patent No. 2005320351

[6]

CHARRIER JD, 2006, Patent No. 2006501176

[7]

CHARRIER JD, Patent No. 1517905

[8]

FUREY BF, 2003, BLOOD, V102

[9]

Giles F CJ, 2006, BLOOD, V108

[10] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation [J].

Giles, Francis J. ;

Cortes, Jorge ;

Jones, Dan ;

Bergstrom, Donald ;

Kantarjian, Hagop ;

Freedman, Steven J. .

BLOOD, 2007, 109 (02) :500-502

← 1 2 3 →